A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo

British Journal of Haematology

Volumn 155, Issue 4, 2011, Pages 426-437

  Ward, Elizabeth ^a   Mittereder, Nanette ^a   Kuta, Ellen ^a   Sims, Gary P ^a   Bowen, Michael A ^a   Dall'Acqua, William ^a   Tedder, Thomas ^b   Kiener, Peter ^c   Coyle, Anthony J ^d   Wu, Herren ^a   Jallal, Bahija ^a   Herbst, Ronald ^a  

^a MEDIMMUNE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Zyngenia Inc   (United States)

^d PFIZER INC   (United States)

Author keywords

CD19; CD20; Leukaemia; Lymphoma; Therapeutic antibody

Indexed keywords

CD19 ANTIBODY; CD19 ANTIGEN; MEDI 551; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LYMPHOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD19; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; HUMANS; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MICE; MICE, SCID; PROTEIN ENGINEERING; RECEPTORS, FC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054970846     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08857.x     Document Type: Article

References (43)

1. Anderson, K.C., Bates, M.P., Slaughenhoupt, B.L., Pinkus, G.S., Schlossman, S.F. & Nadler, L.M. (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood, 63, 1424-1433.
2. Busse, W.W., Katial, R., Gossage, D., Sari, S., Wang, B., Kolbeck, R., Coyle, A.J., Koike, M., Spitalny, G.L., Kiener, P.A., Geba, G.P. & Molfino, N.A. (2010) Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor a antibody, in a phase I study of subjects with mild asthma. Journal of Allergy and Clinical Immunology, 125, 1237-1244.
3. Cardarelli, P.M., Rao-Naik, C., Chen, S., Huang, H., Pham, A., Moldovan-Loomis, M.-C., Pan, C., Preston, B., Passmore, D., Liu, J., Kuhne, M.R., Witte, A., Blanset, D. & King, D.J. (2009) A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunology and Immunotherapy, 59, 257-265.
4. Coiffier, B. (2005a) Monoclonal antibodies in the treatment of indolent lymphomas. Best Practice & Research Clinical Haematology, 18, 69-80.
5. Coiffier, B. (2005b) State-of-the-art therapeutics: diffuse large B-cell lymphoma. Journal of Clinical Oncology, 23, 6387-6393.
6. D'Arena, G., Musto, P., Cascavilla, N., Dell'Olio, M., Di Renzo, N. & Carotenuto, M. (2000) Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. American Journal of Hematology, 64, 275-281.
7. Davis, T.A., Czerwinski, D.K. & Levy, R. (1999) Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clinical Cancer Research, 5, 611-615.
8. Davis, T.A., Grillo-Lopez, A.J., White, C.A., McLaughlin, P., Czuczman, M.S., Link, B.K., Maloney, D.G., Weaver, R.L., Rosenberg, J. & Levy, R. (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Journal of Clinical Oncology, 18, 3135-3143.
9. Desjarlais, J.R., Lazar, G.A., Zhukovsky, E.A. & Chu, S.Y. (2007) Optimizing engagement of the immune system by anti-tumour antibodies: an engineer's perspective. Drug Discovery Today, 12, 898-910.
10. Edwards, J.C.W. & Cambridge, G. (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nature Reviews Immunology, 6, 394-403.
11. Flavell, D.J., Warnes, S.L., Bryson, C.J., Field, S.A., Noss, A.L., Packham, G. & Flavell, S.U. (2006) The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. British Journal of Haematology, 134, 157-170.
12. Ghetie, M.-A., Picker, L.J., Richardson, J.A., Tucker, K., Uhr, J.W. & Vitetta, E.S. (1994) Anti-CD19 inhibits the growth of human B-cell tumour lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood, 83, 1329-1336.
13. Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R. & Catovsky, D. (1998) Levels of expression of CD19 and CD20 in chronic B cell leukaemias. Journal of Clinical Pathology, 51, 364-369.
14. Glennie, M.J., French, R.R., Cragg, M.S. & Taylor, R.P. (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Molecular Immunology, 44, 3823-3837.
15. Grossbard, M.L., Lambert, J.M., Goldmacher, V.S., Spector, N.L., Kinsella, J., Eliseo, L., Coral, F., Taylor, J.A., Blattler, W.A., Epstein, C.L. & Nadler, L.M. (1993) Anti-B4-blocked ricin: a phase I trial of 7-day continous infusion in patients with B-cell neoplasms. Journal of Clinical Oncology, 11, 726-737.
16. Hekman, A., Honselaar, A., Vuist, W.M., Sein, J.J., Rodenhuis, S., ten Bokkel Huinink, W.W., Somers, R., Rümke, P. & Melief, C.J. (1991) Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunology and Immunotherapy, 32, 364-372.
17. Hennessy, B.T., Hanrahan, E.O. & Daly, P.A. (2004) Non-Hodgkin lymphoma: an update. Lancet Oncology, 5, 341-353.
18. Herbst, R., Wang, Y., Gallagher, S., Mittereder, N., Kuta, E., Damschroder, M., Woods, R., Rowe, D.C., Cheng, L., Cook, K., Evans, K., Sims, G.P., Pfarr, D.S., Bowen, M.A., Dall'Acqua, W., Shlomchik, M., Tedder, T.F., Kiener, P., Jallal, B., Wu, H. & Coyle, A.J. (2010) B cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. Journal of Pharmacology and Experimental Therapeutics, 335, 213-222.
19. Horton, H.M., Bernett, M.J., Pong, E., Peipp, M., Karki, S., Chu, S.Y., Richards, J.O., Vostiar, I., Joyce, P.F., Repp, R., Desjarlais, J.R. & Zhukovsky, E.A. (2008) Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Research, 68, 8049-8057.
20. Johnson, N.A., Boyle, M., Bashashati, A., Leach, S., Brooks-Wilson, A., Sehn, L.H., Chhanabhai, M., Brinkman, R.R., Connors, J.M., Weng, A.P. & Gascoyne, R.D. (2009) Diffuse large B cell lymphoma: reduced CD20 expression is associated with inferior survival. Blood, 113, 3773-3780.
21. Kansas, G.S. & Tedder, T.F. (1991) Transmembrane signals generated through MHC class II, CD19, CD20, CD39 and CD40 antigens induce LFA-1-dependent and -independent adhesion in human B cells through a tyrosine kinase-dependent pathway. Journal of Immunology, 147, 4094-4102.
22. Keating, G.M. (2010) Rituximab: a review of its use in chronic lymphocytic leukemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs, 70, 1445-1476.
23. Kennedy, A.D., Beum, P.V., Solga, M.D., DiLillo, D.J., Lindorfer, M.A., Hess, C.E., Densmore, J.J., Williams, M.E. & Taylor, R.P. (2004) Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. Journal of Immunology, 172, 3280-3288.
24. Lapalombella, R., Yu, B., Triantafillou, G., Liu, Q., Butchar, J.P., Lozanski, G., Ramanunni, A., Smith, L.L., Blum, W., Andritsos, L., Wang, D.S., Lehman, A., Chen, C.S., Johnson, A.J., Marcucci, G., Lee, R.J., Lee, L.J., Tridandapani, S., Muthusamy, N. & Byrd, J.C. (2008) Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood, 112, 5180-5189.
25. Leonard, J.P., Friedberg, J.W., Younes, A., Fisher, D., Gordon, L.I., Moore, J., Czuczman, M., Miller, T., Stiff, P., Cheson, B.D., Forero-Torres, A., Chieffo, N., McKinney, B., Finucane, D. & Molina, A. (2007) A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Annals of Oncology, 18, 1216-1223.
26. Leonard, J.P., Schuster, S.J., Emmanouilides, C., Couture, F., Teoh, N., Wegener, W.A., Coleman, M. & Goldenberg, D.M. (2008) Durable complete responses from therapy with combined epratuzumab and rituximab. Cancer, 15, 2714-2723.
27. Loken, M.R., Shah, V.O., Dattilio, K.L. & Civin, C.I. (1987) Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood, 70, 1316-1324.
28. Maloney, D.G. (2005) Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. Journal of Clinical Oncology, 23, 6421-6428.
29. Masuda, K., Kubota, T., Kaneko, E., Iida, S., Wakitani, M., Kobayashi-Natsume, Y., Kubota, A., Shitara, K. & Nakamura, K. (2007) Enhanced binding affinity for FcgRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Molecular Immunology, 44, 3122-3131.
30. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825-2833.
31. Nadler, L.M., Anderson, K.C., Marti, G., Bates, M., Park, E., Daley, J.F. & Schlossman, S.F. (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. Journal of Immunology, 131, 244-250.
32. Nimmerjahn, F. & Ravetch, J.V. (2008) Fcγ receptors as regulators of immune responses. Nature Reviews Immunology, 8, 34-47.
33. Oganesyan, V., Gao, C., Shirinian, L., Wu, H. & Dall'Acqua, W.F. (2008) Structural characterization of human Fc fragment engineered for lack of effector functions. Acta Crystallographica, D64, 700-704.
34. Plosker, G.L. & Figgitt, D.P. (2003) Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Drugs, 63, 803-843.
35. Robak, T. (2007) Recent progress in the management of chronic lymphocytic leukemia. Cancer Treatment Reviews, 33, 710-728.
36. Sato, S., Steeber, D.A. & Tedder, T.F. (1995) The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proceedings of the National Academy of Science USA, 92, 11558-11562.
37. Scheuermann, R.H. & Racila, E. (1995) CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leukemia & Lymphoma, 18, 385-397.
38. Stavenhagen, J.B., Gorlatov, S. & Tuaillon, N. (2007) Fc optimization of therapeutic antibodies enhances their ability to kill tumour cells in vitro and controls tumour expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Research, 67, 8882-8890.
39. Stein, R., Qu, Z., Chen, S., Rosario, A., Shi, V., Hayes, M., Horak, I.D., Hansen, H.J. & Goldenberg, D.M. (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clinical Cancer Research, 10, 2868-2878.
40. Stone, M.J., Sausville, E.A., Fay, J.W., Headlee, D., Collins, R.H., Figg, W.D., Stetler-Stevenson, M., Jain, V., Jaffe, E.S., Solomon, D., Lush, R.M., Senderowicz, A., Ghetie, V., Schindler, J., Uhr, J.W. & Vitetta, E.S. (1996) A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patents with B-cell lymphoma. Blood, 88, 1188-1197.
41. Strauss, S.J., Morschhauser, F., Rech, J., Repp, R., Solal-Celigny, P., Zinzani, P.L., Engert, A., Coiffier, B., Hoelzer, D.F., Wegener, W.A., Teoh, N.K., Goldenberg, D.M. & Lister, T.A. (2006) Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. Journal of Clinical Oncology, 24, 3880-3886.
42. Uckun, F.M., Jaszcz, W., Ambrus, J.L., Fauci, A.S., Gajl-Peczalska, K., Song, C.W., Wick, M.R., Myers, D.E., Waddick, K. & Ledbetter, J.A. (1988) Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood, 71, 13-29.
43. Yazawa, N., Hamaguchi, Y., Poe, J.C. & Tedder, T.F. (2005) Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proceedings of the National Academy of Science USA, 102, 15178-15183.